Opinion|Videos|August 1, 2024
Therapeutic Response and Disease Progression
Author(s)Justin Oldham, MD, MS
An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can multidisciplinary care be optimized when treating patients with IPF?
- Describe the therapeutic response and disease progression of patients taking standard of care therapies (pharmacologic and non-pharmacologic).
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
2
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
3
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
4
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
5
